Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 9/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 9/20 | 0.44 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.37 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30891689 | 1.00 | PDE3B (0.44) | PDE3BPDE3AMAPKAPK2RPS6KA3CSNK2A1 | |
| SCHEMBL2079505 | 0.73 | EGFR (0.33) | EGFR | |
| SCHEMBL29540157 | 0.73 | EGFR (0.33) | EGFR | |
| SCHEMBL31093789 | 0.71 | F11 (0.47) | PDE3BPDE3AMAPKAPK2RPS6KA3CSNK2A1 | |
| SCHEMBL4137137 | 0.71 | F11 (0.47) | PDE3BPDE3AMAPKAPK2RPS6KA3CSNK2A1 | |
| SCHEMBL23225458 | 0.70 | TDO2 (0.46) | PDE3BPDE3AEGFRCA12CA1 | |
| SCHEMBL31042178 | 0.69 | DAO (0.53) | PDE3BPDE3ACA12CA1CA3 | |
| SCHEMBL586351 | 0.69 | DAO (0.53) | PDE3BPDE3ACA12CA1CA3 | |
| SCHEMBL3983234 | 0.69 | PIN1 (0.48) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL1378724 | 0.69 | MAPKAPK2 (0.42) | PDE3BPDE3AMAPKAPK2RPS6KA3CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4284511-B1 | AZAQUINOLINES AS INHIBITORS OF CD38 | BOEHRINGER INGELHEIM INT (DE) | 2025-07-16 | — | — | EP | claimed |
| CN-117580829-A | Quinoline and azaquinolines as inhibitors of CD38 | 勃林格英格翰国际有限公司 | 2024-02-20 | — | — | CN | claimed |
| CN-113710661-A | Compounds and methods for treating cancer | 上海睿跃生物科技有限公司 | 2021-11-26 | — | — | CN | claimed |
| WO-2020200291-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI) , INC. (CN) | 2020-10-08 | — | — | WO | claimed |
| CN-117580829-A | Quinoline and azaquinolines as inhibitors of CD38 | 勃林格英格翰国际有限公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-116323570-A | Compounds and methods for treating diseases | 上海睿跃生物科技有限公司 | 2023-06-23 | — | — | CN | disclosed |
| US-20230093099-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2023-03-23 | — | — | US | disclosed |
| CN-113710661-B | Compounds and methods for treating cancer | 上海睿跃生物科技有限公司 | 2022-11-22 | — | — | CN | disclosed |
| WO-2022068933-A1 | COMPOUNDS AND METHODS OF TREATING DISEASES | CULLGEN (SHANGHAI) , INC. (CN) | 2022-04-07 | — | — | WO | disclosed |
| CN-113710661-A | Compounds and methods for treating cancer | 上海睿跃生物科技有限公司 | 2021-11-26 | — | — | CN | disclosed |
| WO-2020200291-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI) , INC. (CN) | 2020-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230093099-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | TP53, BRCA1, VHL | PDE3B 2751/4885PDE3A 3303/4885MAPKAPK2 4213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.